Gastric inhibitory polypeptide: The neglected incretin revisited

Regulatory Peptides

Volumn 107, Issue 1-3, 2002, Pages 1-13

  Meier, Juris J ^a   Nauck, Michael A ^b   Schmidt, Wolfgang E ^a   Gallwitz, Baptist ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Glucagon like peptide 1; Incretin effect; Insulin secretion; Pathogenesis of type 2 diabetes; Treatment of type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; C PEPTIDE; GLUCAGON; GLUCOSE; LIPID; PANCREAS HORMONE; PEPTIDE FRAGMENT; PROTEIN PRECURSOR; SECRETIN;

ADIPOSE TISSUE; CELL SECRETION; DRUG EFFECT; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INTESTINE CELL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS SECRETION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; GLUCOSE BLOOD LEVEL; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; POSTPRANDIAL STATE; SECRETION; SEQUENCE HOMOLOGY; STOMACH;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMAL; BLOOD GLUCOSE; C-PEPTIDE; COMPARATIVE STUDY; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE; HUMAN; INSULIN; LIPIDS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PANCREATIC HORMONES; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS; SECRETIN; SEQUENCE HOMOLOGY, AMINO ACID; STOMACH; SUPPORT, NON-U.S. GOV'T; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

ANIMALIA;

EID: 0037098963     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00039-3     Document Type: Review

References (165)

1. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane
2. Stimulation of release of insulin by an extract of intestinal mucosa
3. Demonstration of the humoral agent in fat inhibition on gastric secretion
4. Preparation of highly active enterogastrone
5. Further purification of a polypeptide demonstrating enterogastrone activity
6. A gastric inhibitory polypeptide II. The complete amino acid sequence
7. Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure 'gastric inhibitory polypeptide'
8. Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man
9. Plasma insulin response to oral and intravenous glucose administration
10. Intestinal factors in the control of insulin secretion
11. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog
12. The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas
13. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas
14. Stimulation of insulin secretion by gastric inhibitory polypeptide in man
15. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels
16. Pancreatic α- and β-cell responses to GIP infusion in normal man
17. The incretin concept today
18. New developments in the incretin concept
19. GI hormones and insulin secretion. Endocrinology
20. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus
21. Effects of ingestion of triglyceride or galactose on secretion of Gastric Inhibitory Polypeptide and on response to intravenous glucose in normal and diabetic subjects
22. The effect of endogenous Gastric Inhibitory Polypeptide on glucose-induced insulin secretion in mild diabetes
23. Effect of porcine gastric inhibitory polypeptide on β-cell function in Type 1 and Type II diabetes mellitus
24. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state
25. The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes
26. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in Type 2 (noninsulin-dependent) diabetes mellitus
27. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
28. Reduced insulinotropic effect of Gastric Inhibitory Polypeptide in first-degree relatives of patients with type 2 diabetes
29. Signal transmission after GLP-1(7-36)amide binding in RINm5F cells
30. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1
31. Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum
32. Identification of the intestinal cell storing gastric inhibitory polypeptide
33. Localization of gastric inhibitory polypeptide release by intestinal glucose perfusion in man
34. Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man
35. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
36. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man
37. Colocalisation of GLP-1 and GIP in human and porcine intestine
38. The incretin hormones GLP-1 and GIP are partly colocalized in the gut in man, pig and rat (abstract)
39. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man
40. Gastric Inhibitory Polypeptide (GIP) stimulated by fat ingestion in man
41. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
42. Glucose-dependent insulin release from genetically engineered K cells
43. Quantification of the incretin effect in first-degree relatives of type 2 diabetic patients compared to healthy control subjects (abstract)
44. Glucagon-like peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose
45. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine
46. Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholezystokinin-33/-39
47. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
48. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach
49. Degradation of endogenous and exogenous Gastric Inhibitory Polypeptide (GIP) in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide
50. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
51. Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides
52. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)
53. Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides
54. The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man
55. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man; Interactions with glucose, phenylalanine, and cholezystokinin-8
56. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
57. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs
58. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
59. Chronic renal failure: Effect of hemodialysis on gastrointestinal hormones
60. Renal effects on serum gastric inhibitory polypeptide (GIP)
61. All products of proglucagon are elevated in plasma of uremic patients
62. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats
63. The hepatic extraction of gastric inhibitory polypeptide and insulin
64. Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs
65. Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance
66. Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels
67. Gastric inhibitory polypeptide release after oral glucose: Relationship to glucose intolerance, diabetes mellitus and obesity
68. The enteric enhancement of glucose-stimulated insulin release: The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus
69. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice
70. Gastric inhibitory polypeptide in obesity and diabetes mellitus
71. Gastric Inhibitory Polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients
72. Gastric inhibitory polypeptide responses to nutrients in Caucasians and American Indians with obesity and non-insulin-dependent diabetes mellitus
73. Immunoreactive gastric inhibitory polypeptide
74. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
75. Gastric inhibitory polypeptide enhance lipoprotein lipase activity in cultured preadipocytes
76. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat adipose tissue
77. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat
78. Hypersensitivity of adipose tissue to gastric inhibitory polypeptide action in obese Zucker rat
79. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue
80. Inhibition of action of glucagon in adipocytes by gastric inhibitory polypeptide
81. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes
82. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain
83. Functional GIP receptors are present on adipocytes
84. The effect of gastric inhibitory polypeptide on 3T3-L1 adipocytes (abstract)
85. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs
86. Effect of endogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs
87. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride response in rats
88. Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in men
89. Inhibition if GIP/GIPR axis prevents obesity (abstract)
90. Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of intralipid in man
91. Gastric inhibitory polypeptide (GIP) is not the primary mediator of the enterogastrone action of fat in the dog
92. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects
93. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
94. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
95. Gut hormones and diabetes mellitus
96. Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets
97. Interaction of arginine and gastric inhibitory polypeptide on insulin release in man
98. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
99. Glucagon-like peptide-1 [7-36]: A physiological incretin in man
100. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
101. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion
102. Depression of insulin release by Anti-GIP serum after oral glucose in rats
103. Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat
104. Effect of GIP and GLP-1 antagonists on insulin release in the rat
105. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice
106. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling
107. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells
108. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
109. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes
110. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable
111. Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia
112. Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: Evidence for an effect on insulin extraction
113. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose
114. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats
115. Hypo- and hypersecretion of GIP in maturity-onset diabetics (abstract)
116. Role of regulator of G protein signalling in desensitization of the glucose-dependent insulinotrpic peptide receptor
117. The cysteine of the cytoplasmatic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitisation and down-regulation
118. Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (βTC-3) cells to glucose-dependent insulinotropic polypeptide
119. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
120. Glucagon-like peptides
121. Gut hormones as pharmaceuticals: From enteroglucagon to GLP-1 and GLP-2
122. The pathogenesis of NIDDM involvers a defective expression of the GIP receptor
123. Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM: No evidence of association with Japanese NIDDM subjects
124. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: The impact on the pancreatic beta cell response and functional expression studies in Chinese hamster fibroblast cells
125. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
126. Genetics of type 2A- and type 2B-Diabetes mellitus (abstract)
127. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus
128. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
129. Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion
130. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus
131. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
132. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
133. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut
134. Insulinotropic action of glucagon-like peptide 1 (7-37) in diabetic and non-diabetic subjects
135. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans
136. Glucagon-like peptide-1 is a physiologic regulator of food intake in humans
137. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
138. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
139. A role for glucagon-like peptide-1 in the central regulation of feeding
140. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats
141. Repeated intracerebroventricular administration of Glucagon-like Peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat
142. Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivate, NN2211 (abstract)
143. Systemic administration of the long-acting GLP-1 analogue, NN2211, induces lasting and reversible loss of body obesity (abstract)
144. Long-acting GLP-1 derivate NN2211 markedly attenuates diabetes development in the male Zucker diabetic fatty rat (abstract)
145. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
146. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidine
147. Inhibition of dipeptidyl-peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics
148. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
149. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
150. The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents
151. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells
152. 2-terminally modified Gastric Inhibitory Polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity
153. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide
154. DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity (abstract)
155. GIP analogues substituted at Ala2 exhibit improved plasma stability and insulin-releasing activity (abstract)
156. Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal
157. Release of gastric inhibitory polypeptide from cultured canine endocrine cells
158. Gastric inhibitory polypeptide release from a tumor derived cell line
159. Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase
160. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells
161. Current perspectives of biotechnological replacement of insulin secreting cells
162. Regulated hepatic insulin gene therapy of STZ-diabetic rats
163. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach
164. Inhibitory effect of Glucagon-like peptide-1 on small bowel motility
165. GLP-1 for six weeks reduces body weight and improves insulin sensitivity and glycemic control in patients with Type 2 diabetes